Novo Nordisk wants obesity tablet to have same effect as injection

Novo Nordisk aspires to provide an anti-obesity tablet which is as effective as the equivalent semaglutide injection.

Photo: Novo Nordisk Pharmatech/PR

Danish phamaceutical company Novo Nordisk plans for its obesity tablet to cause weight losses amounting to those generated when the molecule semaglutide is administered as an injection, according to Novo Nordisk Executive Vice President of Development, Martin Holst Lange.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs